Two genes were elucidated, EphA2 and PTGS2, that promoted the clonogenicity of EGFR-mutant NSCLC cells, which are of particular interest from a clinical standpoint because they can be inhibited pharmacologically. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.